Signos Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
45
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$20M
- Investors
-
20
Signos General Information
Description
Developer of a weight loss application designed to recommend meals and exercises that transform the weight loss journey. The company's application offers continuous tracking with a wearable glucose sensor, personalized insights from logged meals and daily activities, and interactive guidance, enabling adults focused on weight management to make informed choices about food and movement that support improved metabolic health.
Contact Information
Website
www.signos.comCorporate Office
- 2625 Middlefield Road
- Suite 720
- Palo Alto, CA 94306
- United States
Corporate Office
- 2625 Middlefield Road
- Suite 720
- Palo Alto, CA 94306
- United States
Signos Timeline
Signos Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 27-May-2026 | $20M | Completed | Generating Revenue | ||
| 3. Later Stage VC (Series B) | 20-Jun-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 10-Nov-2021 | $13M | $17M | Completed | Generating Revenue | |
| 1. Seed Round | 30-Dec-2020 | $4M | $4M | Completed | Generating Revenue |
Signos Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| FF Preferred | ||||||||
| Series A | ||||||||
| Seed-1 | 5,372,009 | $0.000100 | $0.37 | $0.37 | 1x | $0.37 | 9.11% | |
| Seed | 7,385,487 | $0.000100 | $0.27 | $0.27 | 1x | $0.27 | 12.52% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Signos Comparisons
Industry
Financing
Details
Signos Competitors (10)
One of Signos’s 10 competitors is Nutrisense, a Formerly VC-backed company based in Wilmington, DE.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nutrisense | Formerly VC-backed | Wilmington, DE | ||||
| GlySens | Venture Capital-Backed | San Diego, CA | ||||
| Welldoc | Venture Capital-Backed | Columbia, MD | ||||
| MySugr | Formerly VC-backed | Vienna, Austria | ||||
| Levels | Venture Capital-Backed | New York, NY |
Signos Signals
Signos Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 450 Ventures | Corporate Venture Capital | Minority | ||
| Blue Cross Blue Shield of Alabama | Corporation | Minority | ||
| DexCom | Corporation | Minority | ||
| CB3 Holdings | Venture Capital | Minority | ||
| Cheyenne Partners | Venture Capital | Minority |
Signos FAQs
-
When was Signos founded?
Signos was founded in 2018.
-
Where is Signos headquartered?
Signos is headquartered in Palo Alto, CA.
-
What is the size of Signos?
Signos has 45 total employees.
-
What industry is Signos in?
Signos’s primary industry is Clinics/Outpatient Services.
-
Is Signos a private or public company?
Signos is a Private company.
-
What is Signos’s current revenue?
The current revenue for Signos is .
-
How much funding has Signos raised over time?
Signos has raised $57M.
-
Who are Signos’s investors?
450 Ventures, Blue Cross Blue Shield of Alabama, DexCom, CB3 Holdings, and Cheyenne Partners are 5 of 20 investors who have invested in Signos.
-
Who are Signos’s competitors?
Nutrisense, GlySens, Welldoc, MySugr, and Levels are some of the 10 competitors of Signos.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process